title: FePt@CoS(2) yolk-shell nanocrystals as a potent agent to kill HeLa cells.
abstract: We report the evaluation of cytotoxicity of a new type of engineered nanomaterials, FePt@CoS(2) yolk-shell nanocrystals, synthesized by the mechanism of the Kirkendall effect when FePt nanoparticles serve as the seeds. The cytotoxicity of FePt@CoS(2) yolk-shell nanocrystals, evaluated by MTT assay, shows a much lower IC(50) (35.5 +/- 4.7 ng of Pt/mL for HeLa cell) than that of cisplatin (230 ng of Pt/mL). In the control experiment, cysteine-modified FePt nanoparticles exhibit IC50 at 12.0 +/- 0.9 microg of Pt/mL. Transmission electron microscopy confirms the cellular uptake of FePt@CoS(2) nanocrystals, and the magnetic properties analysis (SQUID) proves the release of FePt nanoparticles from the yolk-shell nanostructures after cellular uptake. These results are significant because almost none of the platinum-based complexes produced for clinical trials in the past 3 decades have shown higher activity than that of the parent drug, cisplatin. The exceptionally high toxicity of FePt@CoS(2) yolk-shell nanocrystals (about 7 times higher than that of cisplatin in terms of Pt) may lead to a new design of an anticancer nanomedicine.
authors.affiliation: Department of Chemistry, Center for Cancer Research, Department of Physics, and Bioengineering Program, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
authors.forename: Jinhao
authors.initials: J
authors.lastname: Gao
authors.forename: Gaolin
authors.initials: G
authors.lastname: Liang
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.forename: Yi
authors.initials: Y
authors.lastname: Kuang
authors.forename: Xixiang
authors.initials: X
authors.lastname: Zhang
authors.forename: Bing
authors.initials: B
authors.lastname: Xu
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects* / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology / Q000633:toxicity; D003035:Cobalt / Q000494:pharmacology* / Q000633:toxicity; D003545:Cysteine / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D007501:Iron / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles / Q000737:chemistry*; D009944:Organoplatinum Compounds / Q000494:pharmacology* / Q000633:toxicity; D013696:Temperature; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D009944:Organoplatinum Compounds; D003035:Cobalt; D007501:Iron; C027875:cobaltous sulfide; D003545:Cysteine; D002945:Cisplatin